# Left Exit 12 Off Ramp – CED Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/left-exit-12-off-ramp-ced-clinic/ > **Published:** 2026-06-02T23:53:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:23:10-04:00 > **Clinical Summary:** Personalized cannabis dosing strategy based on individual phenotype, not templates, improves safety and efficacy in clinical practice. Learn the evidence. --- ✦ New CED Clinical Relevance #80 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. SleepPainAnxietyMental HealthCBDTHCDosing Dr. Caplan’s Take “What distinguishes responsible [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) from the noise is this: we start by understanding the individual patient in front of us, their specific condition and medication interactions, rather than applying a one-size-fits-all approach that frankly doesn’t work and undermines clinical credibility.” Clinical Perspective This resource emphasizes individualized consultation in cannabis evaluation, which aligns with evolving clinical practice recognizing that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) exists on a spectrum of risk and benefit profiles depending on patient-specific factors. The principle of tailoring assessment to individual circumstances is sound, yet clinicians should remain cautious that such personalized approaches do not substitute for rigorous evidence review, standardized screening tools, and documentation of contraindications. Important confounders include patient self-selection bias when seeking [cannabis consultation](https://cedclinic.com/cannabis-works-differently-than-traditional-medicine/), potential underreporting of adverse effects or [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) risk, and the variable quality of “personalized” guidance depending on provider training and knowledge base. A practical implication for clinical practice is to develop a structured, evidence-informed framework for cannabis discussions that honors individual variation while maintaining fidelity to established risk assessment protocols, drug interaction screening, and documentation of therapeutic goals and monitoring plans. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/sleep/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Left%20Exit%2012%20Off%20Ramp%20-%20CED%20Clinic%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57535)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57535)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Left%20Exit%2012%20Off%20Ramp%20-%20CED%20Clinic%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57535)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis Drug Interaction Check (Free) – Green Bridge Society](https://cedclinic.com/cannabis-drug-interaction-check-free-green-bridge-society/) - [Policy Watch: 10 Regulatory Updates — June 02, 2026](https://cedclinic.com/synthetic-cannabinoids-schedule-i-updates-2026/) - Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I 📰 Source: [https://cedclinic.com/left-exit-12-off-ramp-2/](https://cedclinic.com/left-exit-12-off-ramp/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).